Drug intelligence / Profile preview

EBX-002

Development stage: Preclinical
Lead developer: EnteroBiotix
Administration: Oral

Overview

EBX-002 is an anti-infective candidate developed by EnBiotix, a bioengineering company. It is part of a portfolio of three anti-infective candidates, including EBX-001 and EPP-001. This portfolio is being developed and commercialized in Latin America through a joint venture, EnBiotix (Brasil) Ltda. (EBL), formed with Wired Holdings Investment Corp. (WHIC). EnBiotix later merged with Polyphor to form Spexis AG, which focuses on rare diseases and oncology.

Targets

Bacterial Ribosome

Beyond the preview

Go deeper on EBX-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EBX-002.

Explore the full profile